The detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer

Couper, Graeme; McAteer, Dympna; Wallis, F.; Norton, M. Y.; Welsh, Aimee; Nicolson, M. C.; Sharp, P; Gilbert, FJ; Park, K G M

doi:10.1016/s0016-5085(98)82369-x

Cited by 13 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The potential of this functional method in detecting response to neoadjuvant treatment in a group of patients with upper gastrointestinal malignancy was first published in 1998 (ref. 35 ). Subsequent studies on the ability of 18 F-FDG PET to identify histopathological responders reached conflicting conclusions [23][24][25][26][27][36][37][38][39] .…”

Section: Introductionmentioning

confidence: 99%

The value of <sup>18</sup>F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy

Mysliveček¹,

Neoral²,

Vrba³

et al. 2012

BIOMED PAP

View full text Add to dashboard Cite

Aim.To evaluate the ability of hybrid 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) to predict histopathological response and overall survival (OS) after preoperative neoadjuvant chemoradiotherapy (CRT) in patients with the esophageal carcinoma. Methods. 73 patients with locally advanced esophageal carcinoma were included in the study. All were treated with CRT and 34 subsequently underwent surgical resection of the esophagus. 18F-FDG PET/CT was carried out prior to (PET/ CT1) and 6 weeks after (PET/CT2) completion of the CRT. Results. PET/CT2-determined complete metabolic response (CMR) was achieved in 6 (17.6%) out of 34 operated patients, the metabolic response was incomplete (NCMR) in 28 (82.4%) patients. A histopathological complete response (CR) to CRT was discovered in 7 patients (20.6%). The median OS in operated patients was 17.1 months, 95% CI:12.9-23.3 months. In a group of 39 non-operated patients, CMR after neoadjuvant CRT was achieved in 12 patients (30.8%), while NCMR was found in 28 (82.4%). The median OS was 13.5 months in this group, 95% CI: 4.4-22.7 months. Conclusion. No statistically significant correlation was found between the 18 F-FDG metabolic response after the neoadjuvant CRT and histopathological response. Presently, the contribution of 18 F-FDG PET/CT as a marker of the potential result of CRT cannot be considered definite. Another study with a larger sample of patients and standardized algorithms for the examining protocols would be necessary for reaching definitive conclusions.

show abstract

Section: Introductionmentioning

confidence: 99%

The value of <sup>18</sup>F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy

Mysliveček¹,

Neoral²,

Vrba³

et al. 2012

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…2,3,9,11 Moreover, esophageal carcinoma patients who are responding to chemoradiation by PET have a significant correlation with pathologic response and survival. 9,[12][13][14] PET has been shown to be accurate and sensitive in detecting recurrent esophageal carcinoma as well. 2,3 Despite these findings, the value of baseline PET in patients with localized esophageal and gastroesophageal junction carcinoma in prognosticating outcome has not been established.…”

mentioning

confidence: 99%

Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma

Hong

Lunagómez

Kim

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe value of baseline positron emission tomography (PET) for predicting overall survival (OS) or disease‐free survival (DFS) is unclear in patients with nondistant metastatic (locoregional only) esophageal carcinoma. The authors tested the hypothesis that, in this setting, the number of PET abnormalities (NPA) would correlate with OS and DFS.METHODSThe authors of the current study analyzed patients with localized esophageal carcinoma (Stages II and III) who had a baseline PET and endoscopic ultrasonography (EUS) and were all treated with chemoradiotherapy followed by surgery. The standardized uptake value (SUV) of PET avid lesions were evaluated for: SUV of the primary, NPA, peak SUV, and total SUV. Correlations were performed with baseline EUS results, OS, DFS, and clinical and pathologic response.RESULTSForty‐seven patients who underwent chemoradiotherapy followed by surgery were analyzed. Most patients had clinical Stage III cancer. NPA was significantly associated with OS (Cox model, P = 0.02; log‐rank test, P = 0.04) and DFS (P = 0.04). Patients with NPA > 1 had a death hazard ratio of 4.49 (reference, NPA = 1). In a multivariate analysis, NPA was independently predictive of OS (P = 0.03). Alternatively, SUV of the primary tumor, peak SUV, total SUV, and EUS clinical stage did not correlate with the type of response, OS or DFS.CONCLUSIONSData from the current study suggest that for nondistant metastatic esophageal carcinoma, baseline PET can predict patient outcome. Baseline NPA (> 1), reflecting the regional nodal metastases, is an independent predictor of OS. Baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy. Cancer 2005. © 2005 American Cancer Society.

show abstract

“…40,41) Cisplatin is known to inhibit glucose uptake in various cells. 42,43) In fact, cisplatin rapidly decreases the function of glucose transporter 1 by changing its intracellular localization in ovarian cancer cells. 44) This cisplatin-dependent acute decrease in the removal of glucose from the blood system might increase the risk of hyperglycemia by the administration of olanzapine.…”

Section: Discussionmentioning

confidence: 99%

Administration of Olanzapine as an Antiemetic Agent Changes Glucose Homeostasis in Cisplatin-Treated Rats

Machida

Miyamura

Machida

et al. 2015

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

We investigated the effects of olanzapine on cisplatin-induced pica (the consumption of non-nutrient materials such as kaolin) and glucose homeostasis in rats to clarify the effects of olanzapine when used as an anti-emetic drug. Rats were injected intraperitoneally (i.p.) with either 5 mg/kg cisplatin or saline. Additionally, 2 or 10 mg/kg olanzapine were administered i.p. to the rats 10 min before the administration of cisplatin and subsequently administered every 24 h for 3 d. Kaolin and food intake was measured using an automatic monitoring apparatus. Plasma glucose levels were measured by an enzyme electrode method. The plasma levels of insulin and intact proinsulin were measured by enzyme-linked immunosorbent assay (ELISA). The proinsulin-to-insulin (P/I) ratio was calculated. Cisplatin significantly increased kaolin intake, but decreased food intake and body weight up to 72 h. Olanzapine had no effect on these parameters. Neither olanzapine nor cisplatin alone had a significant effect on the plasma levels of glucose, insulin, or proinsulin. However, a combination of olanzapine and cisplatin significantly decreased plasma insulin levels, but increased plasma intact proinsulin levels and the P/I ratio. Our results suggest that an additive deterioration of insulinsecreting beta-cell function and disturbance of glucose homeostasis should be considered during treatment of patients with olanzapine for cisplatin-induced nausea and vomiting.Key words chemotherapy-induced nausea and vomiting; olanzapine; cisplatin; pica; glucose homeostasis Chemotherapy-induced nausea and vomiting (CINV) is a major adverse event that affects patients' quality of life and is closely related to tolerance of chemotherapy and the rate of success. Therefore, the outcome of chemotherapy itself is influenced by anti-emetic treatments for CINV.1) Animal experimental models and human studies show that acute emesis, which is evoked within the first 24 h after highly emetogenic chemotherapy (HEC), is controlled by the use of selective 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonists, such as granisetron and ondansetron.2,3) Delayed emesis, occurring at 1 d to 1 week after HEC, cannot be controlled by serotonin 5-HT 3 receptor antagonists alone, but can be controlled by the combination of a 5-HT 3 receptor antagonist, dexamethasone, and/or a tachykinin NK 1 receptor antagonist in both human patients 4,5) and ferrets. [6][7][8] In fact, the use of these drugs is widely recommended in the guidelines for CINV prevention, including those of the National Comprehensive Cancer Network. However, CINV is still experienced by patients: approximately 20% of patients experience acute emesis and approximately 30% experience delayed emesis that is uncontrolled by the antiemetic therapy recommended in these guidelines. [9][10][11] Currently, the use of olanzapine is recommended as an alternative option for CINV prophylaxis in such patients. [12][13][14] The detailed mechanism by which olanzapine reduces CINV is still unknown. However, blockade of the ac...

show abstract

The detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer

Cited by 13 publications

References 0 publications

The value of <sup>18</sup>F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy

The value of <sup>18</sup>F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy

Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma

Administration of Olanzapine as an Antiemetic Agent Changes Glucose Homeostasis in Cisplatin-Treated Rats

Contact Info

Product

Resources

About